UK: NICE Seeks Views On Using RWD To Inform Guidance
Executive Summary
NICE, the health technology appraisal body for England and Wales, is consulting on greater use of real world data to develop guidance.
You may also be interested in...
AstraZeneca To Fight NICE Knockback For Tagrisso In England
Following NICE’s rejection last week for Tagrisso, AstraZeneca argues that the health technology appraisal body was wrong not to take the company’s real-world data into account when considering whether the lung cancer drug should be granted “end of life” status.
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.